Riskpilot← Back to searchSign inGet full accessAdermark Neuromed AB
ABActiveOrg 5592558372Orkestergatan 27Educational support activities n.e.c. · NACE 8569Est. 20200 employees
Revenue 2025
SEK 9K
-78% vs 2024
EBITDA margin
54.2%
-87% vs 2024
Equity ratio
61.7%
Financial strength
Net profit 2025
SEK 5K
-85% vs 2024
| Revenue | SEK 9K | -78% |
| EBITDA | SEK 5K | -87% |
| Net profit | SEK 5K | -85% |
| Total assets | SEK 182K | +1% |
| Equity | SEK 112K | +4% |
| Employees | 0 | — |
Legal name
Adermark Neuromed AB
Org number
5592558372
Legal form
Aktiebolag
NACE code
8569 · Educational support activities n.e.c.
Founded
14 maj 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föreläsningar och fortbildning. Föreläsningar om, och granskning av, hälsorelaterad forskning gentemot företag och organisationer. Konsultverksamhet inom medicinsk forskning. Grafisk kommunikation, illustration och layout. Framtagning av material för kunskapsutveckling inom medicinsk vetenskapFörfattande av vetenskaplig litteratur. Samt förvaltning av värdepapper och förenlig verksamhet.
Address
Orkestergatan 27
Email
louise@adermark.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 106 | 2 | 20 | 43 | 9 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | 102 | −3 | 7 | 39 | 5 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 102 | −3 | 7 | 39 | 5 |
| Net financials | — | — | 0 | 1 | 1 |
| Profit before tax | 102 | 10 | 42 | 40 | 6 |
| Tax | −22 | −2 | −9 | −8 | −1 |
| Net profit | 80 | 8 | 33 | 32 | 5 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 194 | 166 | 170 | 179 | 182 |
| Equity | 105 | 113 | 76 | 108 | 112 |
| Long-term debt | 3 | 8 | 92 | 64 | 68 |
| Short-term debt | 38 | 11 | 2 | 7 | 2 |
| Total debt | 41 | 19 | 94 | 72 | 70 |
EBITDA margin
54.2%
This company
15.8%
Market median
+243% vs market
20212025
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
20212025
Return on equity
4.1%
This company
18.4%
Market median
-78% vs market
20212025
Net profit margin
48.5%
This company
8.1%
Market median
+499% vs market
20212025
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20212025
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Adermark Neuromed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svante Gerhard Adermark | Deputy Board Member | 0 companies |
| Anna Louise Adermark | Board of Directors | 0 companies |